Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram

BackgroundSorafenib, a kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC) but provides only a limited survival benefit. Disulfiram (DSF), a drug for treating alcoholism and a chelator of copper (Cu), forms a complex with Cu (DSF/Cu). DSF/Cu is a potent inducer of a...

Full description

Bibliographic Details
Main Authors: Gong Zhang, Yufeng Wang, Bryan C. Fuchs, Wei Guo, David L. Drum, Derek J. Erstad, Baomin Shi, Albert B. DeLeo, Hui Zheng, Lei Cai, Liyuan Zhang, Kenneth K. Tanabe, Xinhui Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
sorafenib
disulfiram
copper
hepatic cancer stem cells
ERK pathway
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.913736/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.913736/full

Similar Items